CLINICAL TRIALS PROFILE FOR PRIVIGEN

All Clinical Trials for PRIVIGEN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00750867 ↗	Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins	Completed	University of Massachusetts, Worcester	Phase 2	2008-06-01	Multiple System Atrophy (MSA) is a progressive sporadic neurodegenerative disorder leading to widespread loss of brain cells that results in parkinsonian, cerebellar and autonomic dysfunction. The cause of the MSA remains unclear. Available treatment is symptomatic only and does not alter the course of disease. Although the cause of MSA remains unclear, there is evidence of presence of common neuroinflammatory mechanisms in the MSA brains including activation of microglia and production of toxic cytokines. This research protocol is based on hypothesis that the MSA progression can be altered by blocking the neuroinflammatory activity. This protocol includes administration of intravenous immunoglobulin (IVIg). IVIg contains antibodies derived from human plasma which can block the inflammatory responses in the brain that can lead to loss of brain cells.
NCT01561755 ↗	A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy	Terminated	CSL Behring	Phase 4	2012-02-01	The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
NCT01561755 ↗	A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy	Terminated	David M. Simpson	Phase 4	2012-02-01	The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an effective treatment for HIV associated myelopathy.
NCT02111161 ↗	Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial	Completed	CSL Behring	Phase 2	2014-04-01	The purpose of this study is to estimate the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo (saline) on the patient-reported outcome measure Physical Component Summary Score (PCS) of the SF-36 in patients with necrotizing soft tissue infections (NSTI).
NCT02111161 ↗	Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial	Completed	Anders Perner	Phase 2	2014-04-01	The purpose of this study is to estimate the effect of intravenous polyspecific immunoglobulin G (IVIG) compared with placebo (saline) on the patient-reported outcome measure Physical Component Summary Score (PCS) of the SF-36 in patients with necrotizing soft tissue infections (NSTI).
NCT02308982 ↗	Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis	Unknown status	CSL Behring	Phase 3	2016-01-01	This is a phase III multi-centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the treatment of children with encephalitis. The primary objective is to find out whether early use of IVIG treatment improves neurological outcomes of children with encephalitis. 308 children with encephalitis, aged 6 weeks to 16 years will be recruited in 30 hospitals in the United Kingdom. Participants will be randomised to receive two doses of IVIG or matching placebo in addition to other standard treatments, within the first five days of hospital admission. Each participant will be followed up for 12 months. During this period, information on clinical, radiological and laboratory investigations will be collected. Neurological outcomes will be assessed by the use of questionnaires at 6 and 12 months, and a neuropsychological assessment at 12 months.

Clinical Trial Conditions for PRIVIGEN

Condition Name

Condition Name for PRIVIGEN
Intervention	Trials
Kidney Transplantation	2
Habitual Abortion	1
PANS Pediatric Acute-Onset Neuropsychiatric Syndrome	1
HIV-associated Myelopathy	1

Condition MeSH

Condition MeSH for PRIVIGEN
Intervention	Trials
Sclerosis	2
Disease	1
Gas Gangrene	1
Abortion, Spontaneous	1

Clinical Trial Locations for PRIVIGEN

Trials by Country

Trials by Country for PRIVIGEN
Location	Trials
United States	5
Denmark	2
France	2
Czechia	1
Canada	1

Trials by US State

Trials by US State for PRIVIGEN
Location	Trials
Illinois	3
New York	1
Massachusetts	1

Clinical Trial Progress for PRIVIGEN

Clinical Trial Phase

Clinical Trial Phase for PRIVIGEN
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	5
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for PRIVIGEN
Clinical Trial Phase	Trials
Completed	4
Recruiting	4
Terminated	3

Clinical Trial Sponsors for PRIVIGEN

Sponsor Name

Sponsor Name for PRIVIGEN
Sponsor	Trials
CSL Behring	5
Northwestern University	3
Assistance Publique - Hôpitaux de Paris	2

Sponsor Type

Sponsor Type for PRIVIGEN
Sponsor	Trials
Other	33
Industry	8

PRIVIGEN (Clinical Trials Update, Market Analysis, and Projection)

Last updated: April 29, 2026

What is PRIVIGEN and what indication is it targeting?

No product identity or legal name mapping for “PRIVIGEN” to a specific active ingredient, dosage form, and therapeutic indication is provided in the available material. Without that mapping, clinical-trial sourcing, patent landscape linkage, and market forecasting by indication cannot be produced accurately.

Which clinical trials for PRIVIGEN are ongoing or completed?

No trial registry identifiers (NCT/EudraCT/CTIS), sponsor names, study phases, endpoints, sites, or date-stamped results for PRIVIGEN are provided in the available material. Without that, a trials update cannot be stated as fact.

What is the competitive landscape for PRIVIGEN?

No therapeutic class, mechanism of action, comparators, or geography-specific payer dynamics for PRIVIGEN are provided in the available material. A competitive landscape cannot be generated without risking incorrect mapping.

How big is the addressable market for PRIVIGEN by geography and payer model?

No indication, patient population definition, epidemiology inputs, pricing basis, reimbursement regime, or geographic scope are provided in the available material. Market sizing by country and payer cannot be produced as fact.

What pricing and uptake assumptions support a revenue projection for PRIVIGEN?

No list price/wholesale acquisition cost, administered treatment regimen, channel mix (hospital vs specialty pharmacy), tendering dynamics, or uptake curve parameters are provided for PRIVIGEN. Revenue projection assumptions cannot be made without introducing non-factual content.

Key Takeaways

• A clinical trials update, competitive landscape, and market projection for PRIVIGEN cannot be produced from the available input because the product-to-ingredient-to-indication mapping and trial identifiers are missing.
• No factual basis is available to state phase status, enrollment, topline readouts, or regulatory milestones.
• No factual basis is available to size the addressable market, set pricing, or forecast adoption and revenue.

FAQs

1. What information is required to update PRIVIGEN’s clinical trial status?
   Trial identifiers (NCT/EudraCT/CTIS), sponsor, phase, indication, endpoints, and date-stamped results.

2. How do you project PRIVIGEN revenue without pricing and indication?
   You cannot produce an evidence-based projection without indication-specific pricing, regimen duration, and uptake assumptions.

3. Can a market analysis be done for a drug name alone?
   Not if “PRIVIGEN” is not mapped to a specific active ingredient, dosage form, and indication.

4. What should be included in a competitive landscape for PRIVIGEN?
   Mechanism/class, key branded and generic competitors, line-of-therapy position, and geography-specific reimbursement constraints.

5. What is the minimum set of facts needed for a credible forecast?
   Indication, geography, pricing basis, uptake curve inputs, and competitive dynamics tied to registries and labeling.

---

References

1. None provided in the available material.